PMID- 36547817
OWN - NLM
STAT- MEDLINE
DCOM- 20230126
LR  - 20230202
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 42
IP  - 2
DP  - 2023 Feb
TI  - Minimal clinically important difference (MCID), substantial clinical benefit 
      (SCB), and patient acceptable symptomatic state (PASS) of upper extremity PROMIS 
      scores in idiopathic adhesive capsulitis.
PG  - 579-589
LID - 10.1007/s10067-022-06479-3 [doi]
AB  - INTRODUCTION: The purpose of this study is to calculate the minimal clinically 
      important difference (MCID), substantial clinical benefit (SCB), and patient 
      acceptable symptom state (PASS) of Patient-Reported Outcomes Measurement 
      Information System (PROMIS) Upper Extremity Computer Adaptive Testing v2.0 (UE), 
      Pain Interference (P-Interference), and Pain Intensity (P-Intensity) in patients 
      treated nonoperatively for idiopathic adhesive capsulitis (IAC). METHODS: The 
      anchor-based MCID, SCB, and PASS were calculated as the change in PROMIS scores 
      representing the optimal cutoff for a ROC curve with an area under the curve 
      (AUC) analysis. The distribution-based MCID was calculated as a range between the 
      average standard error of measurement multiplied by two different constants: 1 
      and 2.77. Effect sizes and standardized response means (SRM) were calculated to 
      assess the responsiveness of each PROMIS instrument while regression analyses 
      were performed to identify factors associated with achieving these thresholds. 
      RESULTS: This study enrolled 115 patients. The anchor-based MCID for PROMIS UE, 
      P-Interference, and P-Intensity was 5.11, 4.16, and 8.16, respectively. The 
      respective SCB was 8.44, 6.65, and 10.05. The respective PASS was 8.47, 7.01, and 
      10.41. The odds of achieving MCID values in adhesive capsulitis were negatively 
      affected by gender (male), higher forward elevation at the time of presentation, 
      higher pain scores (P-Interference), need for >/= 2 corticosteroid injections, and 
      a concomitant diagnosis of diabetes. CONCLUSION: The MCID, SCB, and PASS 
      parameters for PROMIS scores can be utilized to determine the clinical 
      meaningfulness of patient-reported improvements in these instruments during the 
      nonoperative treatment and as a research tool to compare the efficacy of new 
      treatments for adhesive capsulitis. LEVEL OF EVIDENCE: Level III, basic science 
      study, validation of outcome instruments. Key points * This is the first study to 
      calculate the minimal clinically important difference (MCID), substantial 
      clinical benefit (SCB), and patient acceptable symptomatic state (PASS) for the 
      Patient-Reported Outcome Measurement Information System (PROMIS) Upper Extremity 
      and Pain instruments in patients with idiopathic adhesive capsulitis (IAC) of the 
      shoulder.* This study determined the impact of symptom severity, demographics, 
      and comorbidities on achieving the MCID, SCB, and PASS for PROMIS instruments in 
      IAC patients treated nonoperatively.
CI  - (c) 2022. The Author(s), under exclusive licence to International League of 
      Associations for Rheumatology (ILAR).
FAU - Alben, Matthew G
AU  - Alben MG
AUID- ORCID: 0000-0001-7398-4088
AD  - Division of Shoulder and Elbow Surgery, Department of Orthopedic Surgery, NYU 
      Grossman School of Medicine, NYU Langone Orthopedic Hospital, NYU Langone Health, 
      246 East 20Th Street, New York, NY, 10003, USA.
FAU - Gambhir, Neil
AU  - Gambhir N
AUID- ORCID: 0000-0002-1571-0780
AD  - Division of Shoulder and Elbow Surgery, Department of Orthopedic Surgery, NYU 
      Grossman School of Medicine, NYU Langone Orthopedic Hospital, NYU Langone Health, 
      246 East 20Th Street, New York, NY, 10003, USA.
FAU - Shankar, Dhruv
AU  - Shankar D
AUID- ORCID: 0000-0002-4153-9382
AD  - Division of Sports Surgery, Department of Orthopedic Surgery, NYU Grossman School 
      of Medicine, NYU Langone Orthopedic Hospital, NYU Langone Health, 246 East 20Th 
      Street, New York, NY, 10003, USA.
FAU - Gordon, Dan
AU  - Gordon D
AD  - Department of Orthopedic Surgery, Baylor University Medical Center Dallas, 
      Dallas, TX, USA.
FAU - Zuckerman, Joseph D
AU  - Zuckerman JD
AUID- ORCID: 0000-0003-3072-9970
AD  - Division of Shoulder and Elbow Surgery, Department of Orthopedic Surgery, NYU 
      Grossman School of Medicine, NYU Langone Orthopedic Hospital, NYU Langone Health, 
      246 East 20Th Street, New York, NY, 10003, USA.
FAU - Virk, Mandeep S
AU  - Virk MS
AUID- ORCID: 0000-0001-6294-2771
AD  - Division of Shoulder and Elbow Surgery, Department of Orthopedic Surgery, NYU 
      Grossman School of Medicine, NYU Langone Orthopedic Hospital, NYU Langone Health, 
      246 East 20Th Street, New York, NY, 10003, USA. drmandeepvirk@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20221222
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
SB  - IM
MH  - Humans
MH  - Male
MH  - Treatment Outcome
MH  - *Minimal Clinically Important Difference
MH  - Upper Extremity
MH  - *Bursitis/therapy
MH  - Pain
OTO - NOTNLM
OT  - Adhesive capsulitis
OT  - Effect size
OT  - MCID
OT  - PASS
OT  - PROMIS
OT  - SCB
EDAT- 2022/12/23 06:00
MHDA- 2023/01/27 06:00
CRDT- 2022/12/22 11:21
PHST- 2022/08/08 00:00 [received]
PHST- 2022/12/08 00:00 [accepted]
PHST- 2022/12/04 00:00 [revised]
PHST- 2022/12/23 06:00 [pubmed]
PHST- 2023/01/27 06:00 [medline]
PHST- 2022/12/22 11:21 [entrez]
AID - 10.1007/s10067-022-06479-3 [pii]
AID - 10.1007/s10067-022-06479-3 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2023 Feb;42(2):579-589. doi: 10.1007/s10067-022-06479-3. Epub 
      2022 Dec 22.